The frontalis activity measurement standard: A novel contralateral method for assessing botulinum neurotoxin type-A activity

Journal of Drugs in Dermatology

Volumn 10, Issue 9, 2011, Pages 968-972

  Nestor, Mark S ^a   Ablon, Glynis R ^b  

^a Center for Clinical and Cosmetic Research   (United States)

^b Ablon Skin Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN A;

ARTICLE; CLINICAL ASSESSMENT; DOUBLE BLIND PROCEDURE; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; FRONTALIS ACTIVITY MEASUREMENT STANDARD; FRONTALIS MUSCLE; FRONTALIS RATING SCALE; HUMAN; HUMAN EXPERIMENT; MUSCLE; MUSCLE CONTRACTION; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCORING SYSTEM;

BOTULINUM TOXINS, TYPE A; DOUBLE-BLIND METHOD; FACIAL MUSCLES; FOREHEAD; HUMANS; NEUROMUSCULAR AGENTS; TREATMENT OUTCOME;

EID: 80053302651     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Blitzer A, Brin M, Keen M, Aviv J. Botulinum toxin for the treatment of hyperfunctional lines of the face. Arch Otolaryngol Head Neck Surg. 1993;119:1018-1022. (Pubitemid 23270408)
2. ASAPS. Cosmetic Surgery National Data Bank Statistics. Available at: http://www.surgery.org/sites/default/files/2009stats.pdf. Accessed April, 2010.
3. Dysport™ for Injection (abobotulinumtoxinA) Prescribing Information. Medicis Aesthetics, Inc. Scottsdale, AZ. May, 2009.
4. Botox® Cosmetic (onabotulinumtoxinA) for injection Prescribing Information. Allergan, Inc. Irvine, CA. July, 2009.
5. Wenzel R, Jones D, Borrego J. Comparing two botulinum toxin type A formulations using manufacturers' product summaries. J Clin Pharm Ther. 2007;32:387-402. (Pubitemid 47063164)
6. Wohlfarth K, Sycha T, Ranoux D, Naver H, Caird D. Dose equivalence of two commercial preparations of botulinum neurotoxin type A: Time for a reassessment? Curr Med Res Opin. 2009;25:1573-1584.
7. Karsai S, Raulin C. Current evidence on the unit equivalence of different botulinum neurotoxin A formulations and recommendations for clinical practice in dermatology. Dermatol Surg. 2009;35:1-8.
8. Brandt F, Swanson N, Baumann L, Huber B. Randomized, placebo-controlled study of a new botulinum toxin type a for treatment of glabellar lines: Efficacy and safety. Dermatol Surg. 2009;35:1893-1901.
9. Monheit G, Carruthers A, Brandt F, Rand R. A randomized, double-blind, placebo-controlled study of botulinum toxin type A for the treatment of glabellar lines: Determination of optimal dose. Dermatol Surg. 2007;33(suppl):51S-59S.
10. Carruthers J, Lowe N, Menter M, et al. Double-blind, placebo-controlled study of the safety and efficacy of botulinum toxin type A for patients with glabellar lines. Plast Reconstr Surg. 2003;112:1089-1098. (Pubitemid 38251807)
11. Lowe N, Shah A, Lowe P, Patnaik R. Dosing, efficacy and safety plus the use of computerized photography for botulinum toxins type A for upper facial lines. J Cosmet Laser Ther. 2010;12:106-111.
12. Rubin M, Dover J, Glogau R, Goldberg D, Goldman M, Schlessinger J. The efficacy and safety of a new U.S. Botulinum toxin type A in the retreatment of glabellar lines following open-label treatment. J Drugs Dermatol. 2009;8:439-444.
13. Lowe N, Lask G, Yamauchi P, Moore D. Bilateral, double- blind, randomized comparison of 3 doses of botulinum toxin type A and placebo in patients with crow's feet. J Am Acad Dermatol. 2002;47:834-840. (Pubitemid 35403040)
14. Carruthers A, Carruthers J, Hardas B, et al. A validated grading scale for crow's feet. Dermatol Surg. 2008;34(suppl 2):173S-178S.
15. Carruthers A, Carruthers J, Hardas B, et al. A validated grading scale for marionette lines. Dermatol Surg. 2008;34(suppl 2):167S-172S.
16. Carruthers A, Carruthers J, Hardas B, et al. A validated grading scale for forehead lines. Dermatol Surg. 2008;34(suppl 2):155S-160S.
17. Lowe P, Patnaik R, Lowe N. A comparison of two botulinum type A toxin preparations for the treatment of glabellar lines: Double-blind, randomized, pilot study. Dermatol Surg. 2005;31:1651-1654. (Pubitemid 43031167)
18. Hexsel D, Dal'forno T, Hexsel Y, et al. A randomized pilot study comparing the action halos of two commercial preparations of botulinum toxin type A. Dermatol Surg. 2008;34:52-59.
19. Rystedt A, Swartling C, Färnstrand C, Naver H. Equipotent concentrations of Botox and Dysport in the treatment of palmar hyperhidrosis. Acta Derm Venereol. 2008;88:458-461.
20. Wohlfarth K, Schwandt I, Wegner F, et al. Biological activity of two botulinum toxin type A complexes (Dysport and Botox) in volunteers: A double-blind, randomized, dose-ranging study. J Neurol. 2008;255:1932-1939.
21. Trindade de Almeida A, Marques E, de Almeida J, Cunha T, Boraso R. Pilot study comparing the diffusion of two formulations of botulinum toxin type A in patients with forehead hyperhidrosis. Dermatol Surg. 2007;33(1 Spec No):37S-43S.
22. Carruthers A, Carruthers J. A single-center dose-comparison study of botulinum neurotoxin type A in females with upper facial rhytids: Assessing patients' perception of treatment outcomes. J Drugs Dermatol. 2009;8:924-929.
23. Carruthers J, Lowe N, Menter M, et al. A multicenter, double-blind, randomized, placebo-controlled study of the efficacy and safety of botulinum toxin type A in the treatment of glabellar lines. J Am Acad Dermatol. 2002;46:840-849.
24. Ascher B, Zakine B, Kestemont P, et al. A multicenter, randomized, double-blind, placebo-controlled study of efficacy and safety of 3 doses of botulinum toxin A in the treatment of glabellar lines. J Am Acad Dermatol. 2004;51:223-233.